- Chart
- Upturn Summary
- Fund Details
Upturn AI Summary
ProShares UltraShort Nasdaq Biotechnology(BIS)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for BIS
11/20/2026: BIS (1-star) is currently NOT-A-BUY. Pass it for now.
ProShares UltraShort Nasdaq Biotechnology (BIS) is an inverse leveraged exchange-traded fund engineered to achieve -2x the daily performance of the Nasdaq Biotechnology Index via swap agreements. Backed by ProShare Advisors, it features standard operational costs with a 0.95% expense ratio, but struggles with a small asset base (~$1.9M) and low trading volume. Its primary use case is short-term tactical hedging or bearish speculation during expected biotechnology downturns. Key risks include severe long-term compounding decay, high sector volatility, and acute sensitivity to positive clinical or macroeconomic catalysts. It is designed exclusively for experienced, active traders rather than long-term buy-and-hold investors, requiring close intraday monitoring.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Weak fit | Growth investors seek capital appreciation, whereas BIS is an inverse fund designed to lose value during sector growth phases. |
| Momentum investor | Strong fit while signal remains positive | Short-term momentum traders capitalizing on sudden, sharp biotech downturns can utilize BIS for tactical bearish plays. |
| Value investor | Weak fit | Value investors focus on fundamental underlying asset worth rather than short-term derivative-based hedging tools. |
| Dividend/Income investor | Weak fit | The fund does not target fundamental equity income and is unsuited for income-generation goals. |
| Low-risk investor | Weak fit | High volatility and severe compounding decay make this product exceptionally risky for conservative investors. |
Investor Profile
Ideal Investor Profile
Sophisticated short-term tactical traders or risk managers seeking intraday or very short-term inverse exposure to the biotechnology sector.
Suitability
Strictly suited for active daily trading and hedging; entirely inappropriate for buy-and-hold or long-term retail investors due to compounding decay.
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Volatility | High | Amplified daily tracking targets cause rapid and severe price fluctuations. |
| Market risk | High | Adverse upward movements in the biotechnology sector result in immediate, steep losses. |
| Concentration | High | The underlying index focuses narrowly on the biotechnology and pharmaceutical industries. |
| Tracking/expense | Medium / high | Compounding effects over holding periods longer than one day cause material deviation from the nominal -2x objective. |
| Liquidity | High | Low assets and modest trading volumes can introduce execution friction and wider spreads. |
| Business/sector quality | Medium / high | Biotech stocks are heavily sensitive to binary clinical events and regulatory decisions. |
Sector & Industry Intelligence
This fund is not assigned to one sector.
Risk Analysis
Volatility
BIS exhibits extreme historical volatility due to its -2x daily leverage target compounding against a volatile underlying sector.
Market Risk
Subject to intense directional market risk, where upward momentum in biotechnology stocks results in rapid capital loss.
What the ETF Owns
| Exposure Type | Exposure | Weight (%) | Retail Investor Read |
|---|---|---|---|
| Derivatives | Nasdaq Biotechnology Index Swap Agreements — seeks -2x daily return | 65 | Provides the structural -2x daily inverse exposure to the performance of the underlying biotechnology index. |
| Cash/collateral | U.S. Dollar Cash & Equivalents | 35 | Serves as collateral backing the fund's swap contracts and daily operational liquidity. |
Price Behavior

Steep Decline
The stock price has dropped sharply with strong downward pressure.

Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type ETF | Historic Profit -27.41% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | ETF Returns Performance |

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

